2. Academic Validation
  3. Loss of CYLD promotes splenic marginal zone lymphoma

Loss of CYLD promotes splenic marginal zone lymphoma

  • Hemasphere. 2025 Mar 17;9(3):e70098. doi: 10.1002/hem3.70098.
Athanasios Pseftogas 1 2,  Jessica Bordini 2,  Silvia Heltai 1,  Ferdinando Bonfiglio 3 4,  Georgios Gavriilidis 5,  Vasileios Vasileiou 5 6,  Sofoklis Keisaris 5,  Daniela Belloni 1 2,  Caterina Taccetti 7,  Pamela Ranghetti 2,  Eleonora Perotta 2,  Michela Frenquelli 2,  Uday Aditya Sarkar 8,  Elisa Albi 2,  Francesca Martini 2,  Emmanuela Sant'Antonio 2,  Fabrizio Mavilia 2,  Fotis Psomopoulos 5,  Manasori Daibata 9,  José Ángel Martínez Climent 10,  George Mosialos 11,  Davide Rossi 12,  Alessandro Campanella 1,  Lydia Scarfò 1 2,  Kostas Stamatopoulos 5,  Konstantinos Xanthopoulos 11,  Paolo Ghia 1 2
Affiliations

Affiliations

  • 1 Università Vita-Salute San Raffaele Milano Italy.
  • 2 IRCCS Ospedale San Raffaele Milano Italy.
  • 3 University of Naples Federico II Napoli Italy.
  • 4 CEINGE Biotecnologie avanzate s.c.a r.l. Napoli Italy.
  • 5 CERTH Thessaloniki Greece.
  • 6 Democritus University of Thrace Alexandropoulis Greece.
  • 7 IFOM, the FIRC Institute of Molecular Oncology Milano Italy.
  • 8 Dana-Farber Cancer Institute Boston Massachusetts USA.
  • 9 Kochi Medical School Kochi Japan.
  • 10 Cima University Navarra Spain.
  • 11 Aristotle University of Thessaloniki Thessaloniki Greece.
  • 12 The Oncology Institute of Southern Switzerland Bellinzona Switzerland.
PMID: 40098895 DOI: 10.1002/hem3.70098
Abstract

Splenic marginal zone lymphoma (SMZL) is a distinct clinical and pathological entity among marginal zone lymphomas. Genetic and microenvironmental factors leading to aberrant activation of the NF-κB pathway have been implicated in SMZL pathogenesis. CYLD is a negative regulator of NF-κB and Other signaling pathways acting as a Deubiquitinase of regulatory molecules and has been reported as a tumor suppressor in different types of Cancer, including B-cell malignancies. To assess whether CYLD is implicated in the natural history of SMZL, we profiled primary cells from patients with SMZL and SMZL cell lines for CYLD expression and functionality. We report that CYLD is downregulated in patients with SMZL and that CYLD ablation in vitro leads to NF-κB pathway hyperactivation, promoting the proliferation of SMZL cells. In addition, we found that CYLD deficiency was associated with increased migration of SMZL cells in vitro, through CCR7 receptor signaling, and with increased dissemination in vivo. CYLD loss was sufficient to induce BcR signaling, conferring increased resistance to ibrutinib treatment in vitro. In summary, our work uncovers a novel role of CYLD as a key regulator in SMZL pathogenesis, dissemination, and resistance to targeted agents. On these grounds, CYLD could be proposed as a novel target for patient stratification and personalized interventions.

Figures
Products